Featured Story | By Amirah Al Idrus Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients whose cancer is linked to a genetic condition called Von Hippel-Lindau disease. The drug also shrank tumors in other parts of the body, including in the pancreas, brain and spinal cord. read more |
| |
|---|
|
|  | Sterile Filling with Eurofins Eurofins BioPharma Product Testing can help eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 trials using our state-of-the-art vial filler. Learn More. |
Top Stories By Ben Adams The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder, especially after AstraZeneca’s trial was briefly stopped in the U.K. (and is still on hold in the U.S.). read more By Angus Liu It looked like the end of road for the idea of targeting IL-6 to control serious pneumonia in COVID-19 patients when Sanofi and Regeneron’s Kevzara and Roche’s Actemra both flopped in clinical trials. But now, the Swiss pharma’s contender has staged a comeback—sort of. read more Sponsored by: Fierce Biotech The Fierce Innovation Awards: Life Sciences Edition have come to a close and we're pleased to announce the 2020 award winners! read more By Nick Paul Taylor Brii Biosciences has hired Rogers Yongqing Luo away from Gilead to serve as general manager of its Chinese operation. The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession. read more By Amirah Al Idrus Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor. But it did better—as expected—in a subset of patients whose tumors expressed PD-L1 at levels of 1% or higher. read more By Nick Paul Taylor MPM Capital has hired Matthew Roden as executive partner. The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs. read more By Ben Adams Alkermes is making a bit bet on its immuno-oncology program after swingeing cuts and R&D setbacks over the past year left its I-O program as one of its leading pipeline hopes. read more By Conor Hale Diagnostic maker Cellex has announced plans to develop a rapid coronavirus infection test that people can fully perform at home, from sample collection to result—with 15-minute readings double-checked by a personal smartphone app. read more By Angus Liu Takeda opened a new cell therapy R&D manufacturing center in Boston. Celltrion's COVID-19 antibody drug passed an early safety test. Bristol Myers Squibb penned a Revlimid patent settlement with Dr. Reddy's. And more. read more By Kyle Blankenship AZ veteran Bohen joins Olema Oncology as CEO; Cygnal Therapeutics taps Wagner as CMO; Dawkins one of two R&D execs hired at Forma. read more |  | LabConnect is now offering global analytical and operational services to meet your COVID-19 testing requirements. We offer viral load testing by RT-qPCR and multiple COVID-19 screening assays. Connect with LabConnect today. We are here to help. |
Resources Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
